Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
AtriCure (ATRC) Q2-25 10-Q highlights: Revenue rose 17.1% YoY to $136.1 M, driven by 41% growth in Pain Management and 19% in Appendage Management; Minimally Invasive Ablation fell 34%. International sales advanced 23% (20% cc). Six-month revenue reached $259.8 M, +15.4% YoY.
Gross margin held at 74.5%. Operating loss narrowed to $6.2 M from $7.2 M; net loss improved to $6.2 M (-$0.13 EPS) vs. $8.0 M (-$0.17). YTD net loss nearly halved to $12.9 M. Cash flow from operations swung to +$10.6 M (vs. -$13.6 M). Cash & equivalents ended at $117.8 M; long-term ABL debt unchanged at $61.9 M, leaving $61.9 M in unused capacity.
R&D expense jumped 43% to $29.3 M, including a $5 M milestone for the pulsed-field ablation (PFA) Cooperation Agreement. SG&A rose 6.5% on headcount. Key milestones: FDA 510(k) clearances for AtriClip PRO-Mini and cryoICE cryoXT (launches 2H-25); completion of 6,500-patient LeAAPS stroke-prevention trial enrollment.
Risk factors: a Delaware suit from former SentreHEART holders seeks up to $260 M over PMA milestone; management deems loss not probable/estimable. Minimally invasive revenue weakness and flat margins bear monitoring.